Detecting renal cancer using liquid biopsy techniques

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the alterations in glycosaminoglycans (GAGs) in plasma and urine samples from patients suspected of having renal tumors. It aims to determine whether these GAG alterations are specific to renal cell carcinoma (RCC) or if they are also present in benign kidney lesions like oncocytomas. The study will include patients with confirmed histological diagnoses of ccRCC or oncocytoma, as well as those with suspicious CT scans showing no signs of renal cancer. The findings could provide insights into the specificity of GAGs as biomarkers for renal cancer detection.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients who underwent CT-scan with suspicion of renal tumor and the scans show no sign of renal cancer.
2. For patient with ccRCC or oncocytoma, they should have a histological verified tumor (Biopsy or surgical specimen)
3. Sign up information consent
4. Can perform protocol procedure

Exclusion Criteria:

1. Non-clear cell Renal cell carcinoma
2. RCC with pure sarcomatoid differentiation, also called sarcoma of the kidney
3. Use of heparin for concurrent disease in need of blood dilution (e.g. ongoing deep vein thrombosis or lung emboli). Note: use of of heparin for thrombus prophylaxis in conjunction with primary surgery or postoperatively ≤4 weeks will be allowed.

Where it's running

• Zealand University Hospital
  Roskilde, Denmark Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Irreversible Electroporation for Recurrent Pelvic Tumors

  This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT07782164

• Registry of Minimally Invasive Cancer Treatments Using Spectral Angio-CT Guidance

  This registry collects data from adults undergoing image-guided, minimally invasive cancer treatments to see if spectral angio-CT guidance helps predict outcomes and improve planning.

  Recruiting Leiden University Medical Center · Lyon, Auvergne-Rhône-Alpes and 2 other locations · NCT07636148

• Hospital admissions for blood in the urine

  This international observational project will look at how hospitals manage adults admitted with blood in the urine to see which approaches lead to shorter stays and better outcomes.

  Recruiting British Urology Researchers in Surgical Training · London · NCT07395037

• SL-28 for Advanced Solid Tumours

  A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Second Life Therapeutics · Sydney, New South Wales and 2 other locations · NCT07341737

• Spectral CT during embolization and ablation for liver and kidney tumors

  This pilot tries a new spectral CT technique during image-guided embolization and ablation for adults with liver or kidney tumors to see if it improves image quality and helps guide treatment.

  Recruiting Palo Alto Veterans Institute for Research · Palo Alto, California · NCT07303725

• Image-guided stereotactic body radiotherapy for primary kidney cancer (STONE)

  This will try high-dose, focused radiation (SBRT) to treat adults with a single small primary kidney cancer who are not good candidates for surgery or who decline surgery.

  Recruiting Istituto Clinico Humanitas · Milan, Milan and 1 other locations · NCT07299357

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.